Business Description
AFT Pharmaceuticals Ltd
ISIN : NZAFTE0001S4
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.4 | |||||
Debt-to-EBITDA | 1.48 | |||||
Interest Coverage | 4.56 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.52 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19.1 | |||||
3-Year EBITDA Growth Rate | 30.1 | |||||
3-Year EPS without NRI Growth Rate | 26 | |||||
3-Year Book Growth Rate | 33.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 17.85 | |||||
Future 3-5Y Total Revenue Growth Rate | 15.2 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.72 | |||||
Quick Ratio | 1.22 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 167.69 | |||||
Days Sales Outstanding | 70.27 | |||||
Days Payable | 91.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 2.03 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 44.12 | |||||
Operating Margin % | 7.48 | |||||
Net Margin % | 5.9 | |||||
ROE % | 14.18 | |||||
ROA % | 7.38 | |||||
ROIC % | 8.23 | |||||
ROC (Joel Greenblatt) % | 39.04 | |||||
ROCE % | 17.74 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 25.54 | |||||
Forward PE Ratio | 19.38 | |||||
PE Ratio without NRI | 25.54 | |||||
Price-to-Owner-Earnings | 27.77 | |||||
PEG Ratio | 1.15 | |||||
PS Ratio | 1.52 | |||||
PB Ratio | 3.58 | |||||
Price-to-Free-Cash-Flow | 17.55 | |||||
Price-to-Operating-Cash-Flow | 11.63 | |||||
EV-to-EBIT | 15.8 | |||||
EV-to-EBITDA | 14.19 | |||||
EV-to-Revenue | 1.64 | |||||
EV-to-FCF | 18.85 | |||||
Earnings Yield (Greenblatt) % | 6.33 | |||||
FCF Yield % | 5.71 | |||||
Forward Rate of Return (Yacktman) % | 21.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AFTPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
AFT Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | 0 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 0 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 0 - 0 | ||
Shares Outstanding (Mil) | 104.87 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
AFT Pharmaceuticals Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
AFT Pharmaceuticals Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
AFT Pharmaceuticals Ltd Frequently Asked Questions
What is AFT Pharmaceuticals Ltd(AFTPF)'s stock price today?
When is next earnings date of AFT Pharmaceuticals Ltd(AFTPF)?
Does AFT Pharmaceuticals Ltd(AFTPF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |